Drugs / Aipalolitovorelizumab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07229846 | Feb 2026 → Feb 2027 expected | colorectal cancer | Yanqiao Zhang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07229872 | Dec 2025 → Dec 2026 expected | colorectal cancer | Harbin Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aipalolitovorelizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07229872 ↗ |
| Known as | QL1706 | “Aipalolitovorelizumab (QL1706) injection at a dose of 5mg/kg, administered intravenously on Day 1 of each 3-week treatment cycle.” NCT07229872 ↗1“Aipalolitovorelizumab (QL1706) Injection: 5 mg/kg, intravenous infusion (ivgtt), d1, Q3W;” NCT07229846 ↗ |
| Route | Intravenous | “intravenous infusion (ivgtt)” NCT07229846 ↗ |